Anshul Sharma

Dr. Anshul Sharma

Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Kaushik DasKaushik Das
Kaushik Das
SPSubhojit Paul
Subhojit Paul
AGArnab Ghosh
Arnab Ghosh
Saurabh GuptaSaurabh Gupta
Saurabh Gupta
TMTanmoy Mukherjee
Tanmoy Mukherjee
Deepak ParasharDeepak Parashar
Deepak Parashar
Triple–negative breast cancer (TNBC) is an aggressive subtype accounting for ~10–20% of all human BC and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. Owing to its unique molecular profile and limited targeted therapies, TNBC treatment poses significant challenges. Unlike other BC subtypes, TNBC lacks specific molecular targets, rendering endocrine therapies and HER2–targeted treatments ineffective. The chemotherapeutic regimen is the predominant systemic treatment modality for TNBC in current clinical practice. However, the efficacy of chemotherapy in TNBC is variable, with response rates varying between a wide range of patients, and the emerging resistance further adds to the difficulties. Furthermore, TNBC exhibits a higher mutational burden and is acknowledged as the most immunogenic of all BC subtypes. Consequently, the application of immune checkpoint inhibition has been investigated in TNBC, yielding promising outcomes. Recent evidence identified extracellular vesicles (EVs) as an important contributor in the context of TNBC immunotherapy. In view of the extraordinary ability of EVs to transfer bioactive molecules, such as proteins, lipids, DNA, mRNAs, and small miRNAs, between the cells, EVs are considered a promising diagnostic biomarker and novel drug delivery system among the prospects for immunotherapy. The present review provides an in–depth understanding of how EVs influence TNBC progression, its immune regulation, and their contribution as a predictive biomarker for TNBC. The final part of the review focuses on the recent key advances in immunotherapeutic strategies for better understanding the complex interplay between EVs and the immune system in TNBC and further developing EV–based targeted immunotherapies.

29 July 2023 in Cells
Verified
Journal Article
Open access
PDF file
Kaushik DasKaushik Das
Kaushik Das
SPSubhojit Paul
Subhojit Paul
TMTanmoy Mukherjee
Tanmoy Mukherjee
AGArnab Ghosh
Arnab Ghosh
ASAnshul Sharma
Anshul Sharma
Deepak ParasharDeepak Parashar
Deepak Parashar
Inflammation is the defense mechanism of the immune system against harmful stimuli such as pathogens, toxic compounds, damaged cells, radiation, etc., and is characterized by tissue redness, swelling, heat generation, pain, and loss of tissue functions. Inflammation is essential in the recruitment of immune cells at the site of infection, which not only aids in the elimination of the cause, but also initiates the healing process. However, prolonged inflammation often brings about several chronic inflammatory disorders; hence, a balance between the pro- and anti-inflammatory responses is essential in order to eliminate the cause while producing the least damage to the host. A growing body of evidence indicates that extracellular vesicles (EVs) play a major role in cell–cell communication via the transfer of bioactive molecules in the form of proteins, lipids, DNA, RNAs, miRNAs, etc., between the cells. The present review provides a brief classification of the EVs followed by a detailed description of how EVs contribute to the pathogenesis of various inflammation-associated diseases and their implications as a therapeutic measure. The latter part of the review also highlights how EVs act as a bridging entity in blood coagulation disorders and associated inflammation. The findings illustrated in the present review may open a new therapeutic window to target EV-associated inflammatory responses, thereby minimizing the negative outcomes.

19 January 2024
Verified
Book Chapter
Closed access
TSTarubala Sharma
Tarubala Sharma
VKVishal Khandelwal
Vishal Khandelwal
SGSaurabh Gupta
Saurabh Gupta
ASAnupam Singh
Anupam Singh
RKRasanpreet Kaur
Rasanpreet Kaur
VKVivek K. Kashyap
Vivek K. Kashyap

30 April 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
VGViney Gupta
Viney Gupta
APARNAV PANIGRAHI
ARNAV PANIGRAHI
BSBindu I Somarajan
Bindu I Somarajan
SGShikha Gupta
Shikha Gupta
KTKoushik Tripathy
Koushik Tripathy
ASArundhati Sharma
Arundhati Sharma
Purpose: To investigate the molecular basis of congenital glaucoma in a family with GAPO (growth retardation, alopecia, pseudoanodontia, and progressive optic atrophy) syndrome. Methods: We report ocular features of 3 girls with GAPO syndrome born of consanguineous marriage in a multi- generation consanguineous family. The proband (4year old girl) and her younger sibling (1 year old girl) were operated for bilateral congenital glaucoma in both eyes. The elder sibling (10year old female) had features of GAPO syndrome but did not manifest features of glaucoma. Results: A genetic evaluation using whole exome sequencing revealed a homozygous ANTXR1 mutation in all 3 affected siblings with GAPO. No other mutations were detected in the genes associated with glaucoma. A rare missense mutation in TGFBI gene was shared in the two siblings with congenital glaucoma and GAPO syndrome.Conclusions: Mutations in TGFBI gene could have a role in the pathogenesis of congenital glaucoma.

11 February 2026 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
ASAnshul Sharma
Anshul Sharma
NSNamrata Sharma
Namrata Sharma
TATushar Agarwal
Tushar Agarwal
ASArundhati Sharma
Arundhati Sharma
RVRasik B Vajpayee
Rasik B Vajpayee
Purpose: Posterior polar cataract (PPC), a rare congenital cataract, is characterized by subcapsular opacities in the lens affecting vision and posing surgical challenges. Genetic heterogeneity exists, though several genes are implicated in its pathogenesis. This study reports on the genetic profile of late-onset PPC cases and identifies variations specific to posterior capsular rupture (PCR) during surgery. Methods: Detailed clinical and genetic history was documented from 100 clinically diagnosed PPC patients and 100 controls. Whole-exome sequencing (WES) was performed in 30 patients and 15 controls, and pathogenic variants were validated in 70 patients and 85 controls by Sanger sequencing. Results: Bilateral PPC was seen in 58%, sporadic cases were 61%, while 39% had a family history. Phacoemulsification was performed on 89 patients, with 12 patients experiencing PCR. Analysis revealed novel and reported variations in the genes – CRYAB (c.328T>G; p.C110G), CRYGB – (c.331A>C; p.I111L), (c.44G>A; p.R15H), CRYBG3 – ( c.1115C>T; p.S372F), CRYBA1 - (c.516A>C; p.G172H), along with EPHA2 (c.1114 G>A; p.E372K), GJA3- (c.895C>A; p.L299M), and PITX3 (c.285C>T; p.I95I). CRYBG3 and GJA3 variations were common among the PCR cases. Conclusion: Results indicate genetic heterogeneity with no mutation hotspots, and the absence of PITX3 variations in our patient cohort is interesting. The study highlights the importance of mutation screening and genotype–phenotype relationships and underscores the importance of accurate diagnosis for enhanced cataract care and management. Subsequent functional studies on the role of these genes may help in understanding normal lens development and provide insights for advanced surgical approaches.